MICHAEL TRAN: Open Payments
NPI 1952513830 · ANDERSON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$618 in 34 payments from 10 companies in 2025. Trend: 2023 $540 · 2024 $610 · 2025 $618
Food & beverage: $618
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 10 | $185 |
| ABBVIE INC. | 9 | $168 |
| Neurocrine BioSciences, Inc. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Janssen Pharmaceuticals, Inc | 3 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: COBENFY, VRAYLAR, INGREZZA, REXULTI, INVEGA SUSTENNA, CAPLYTA, Auvelity, SPRAVATO.
Industry payments across SC — which companies pay providers there.
